# Fortress Biotech, Inc.: overview FBIO · Nasdaq · CIK 1429260 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/fbio.md) · [Financials](/companies/fbio/financials.md) · [Filings](/companies/fbio/filings.md) · [Insiders](/companies/fbio/insiders.md) Latest reported revenue: [$18.7m](/filings/0001104659-26-095964.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 13, 2026 (XBRL us-gaap:Revenues, accession 0001104659-26-095964). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [14.6](/filings/0001104659-25-111989.md) | [15.1 d](/filings/0001104659-26-037874.md) | [13.1](/filings/0001104659-26-061233.md) | [16.4](/filings/0001104659-26-095964.md) | [17.6](/filings/0001104659-25-111989.md) | [16.1 d](/filings/0001104659-26-037874.md) | [16.0](/filings/0001104659-26-061233.md) | [18.7](/filings/0001104659-26-095964.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(151.0%)](/filings/0001104659-25-111989.md) | [(157.6%) d](/filings/0001104659-26-037874.md) | [(169.9%)](/filings/0001104659-26-061233.md) | [(222.2%)](/filings/0001104659-26-095964.md) | [(38.6%)](/filings/0001104659-25-111989.md) | [(29.8%) d](/filings/0001104659-26-037874.md) | [(48.3%)](/filings/0001104659-26-061233.md) | [(53.5%)](/filings/0001104659-26-095964.md) | | Net margin | % | [(88.0%)](/filings/0001104659-25-111989.md) | [(44.7%) d](/filings/0001104659-26-037874.md) | [(80.6%)](/filings/0001104659-26-061233.md) | [94.4%](/filings/0001104659-26-095964.md) | [33.2%](/filings/0001104659-25-111989.md) | [(24.5%) d](/filings/0001104659-26-037874.md) | [688.2%](/filings/0001104659-26-061233.md) | [(2.5%)](/filings/0001104659-26-095964.md) | | Diluted EPS | $ per share | [(0.76)](/filings/0001104659-25-111989.md) | not reported | [(0.48)](/filings/0001104659-26-061233.md) | [0.45](/filings/0001104659-26-095964.md) | [0.11](/filings/0001104659-25-111989.md) | not reported | [2.82](/filings/0001104659-26-061233.md) | [(0.08)](/filings/0001104659-26-095964.md) | | Free cash flow | $m | [(20.1) d](/filings/0001104659-25-111989.md) | [(12.9) d](/filings/0001104659-26-037874.md) | not reported | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [68.8](/filings/0001558370-23-005282.md) | [75.7](/filings/0001558370-24-004272.md) | [84.5](/filings/0001558370-25-004160.md) | [57.7](/filings/0001104659-26-037874.md) | [63.3](/filings/0001104659-26-037874.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(274.1%)](/filings/0001558370-23-005282.md) | [(268.8%)](/filings/0001558370-24-004272.md) | [(168.4%)](/filings/0001558370-25-004160.md) | [(191.4%)](/filings/0001104659-26-037874.md) | [(111.0%)](/filings/0001104659-26-037874.md) | | Net margin | % | [(94.1%)](/filings/0001558370-23-005282.md) | [(114.3%)](/filings/0001558370-24-004272.md) | [(71.7%)](/filings/0001558370-25-004160.md) | [(79.8%)](/filings/0001104659-26-037874.md) | [10.8%](/filings/0001104659-26-037874.md) | | Diluted EPS | $ per share | [(0.79)](/filings/0001558370-23-005282.md) | [(15.97)](/filings/0001558370-24-004272.md) | [(8.47)](/filings/0001558370-25-004160.md) | [(2.69)](/filings/0001104659-26-037874.md) | [(0.07)](/filings/0001104659-26-037874.md) | | Free cash flow | $m | [(121)](/filings/0001558370-23-005282.md) | [(182)](/filings/0001558370-24-004272.md) | [(128)](/filings/0001558370-25-004160.md) | [(80.2)](/filings/0001104659-26-037874.md) | not reported | - Revenue. XBRL Revenue: us-gaap:Revenues. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/fbio/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $3.2m | 1,037,203 | | Added +71,173 | | [Opaleye Management Inc.](/funds/1595855.md) | 2026-06-30 | $2.7m | 890,000 | | Reduced −152,000 | | [MACKENZIE FINANCIAL CORP](/funds/919859.md) | 2026-06-30 | $1.7m | 555,676 | | New +555,676 | | [SUSQUEHANNA INTERNATIONAL GROUP, LLP](/funds/1446194.md) | 2026-06-30 | $1.1m | 356,000 | Put | Added +71,700 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $919.9k | 300,521 | | Added +10,266 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $687.8k | 224,782 | | Added +27,697 | | [TWO SIGMA INVESTMENTS, LP](/funds/1179392.md) | 2026-06-30 | $654.2k | 213,786 | | Added +16,961 | | [BRIDGEWAY CAPITAL MANAGEMENT, LLC](/funds/1107261.md) | 2026-06-30 | $542.7k | 177,368 | | Reduced −5,000 | | [VANGUARD FIDUCIARY TRUST CO](/funds/933478.md) | 2026-06-30 | $509.1k | 166,371 | | Added +23,836 | | [HB Wealth Management, LLC](/funds/1911253.md) | 2026-06-30 | $357.0k | 116,675 | | Reduced −3,500 | ## Recent filings [All 884 filings](/companies/fbio/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-01 | 16:30 ET | [8-K](/filings/0001104659-26-112845.md) | 8.01 Other events | 0001104659-26-112845 | | 2026-08-13 | 16:31 ET | [10-Q](/filings/0001104659-26-095964.md) | Quarterly report, period 2026-06-30 | 0001104659-26-095964 | | 2026-08-13 | 16:15 ET | [8-K](/filings/0001104659-26-095931.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-26-095931 | | 2026-06-23 | 16:05 ET | [8-K](/filings/0001104659-26-076811.md) | 5.07 Shareholder vote results | 0001104659-26-076811 | | 2026-05-14 | 16:31 ET | [10-Q](/filings/0001104659-26-061233.md) | Quarterly report, period 2026-03-31 | 0001104659-26-061233 | | 2026-05-14 | 16:23 ET | [8-K](/filings/0001104659-26-061208.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-26-061208 | | 2026-04-28 | 16:15 ET | [DEF 14A](/filings/0001104659-26-050358.md) | Proxy statement, period 2026-06-17 | 0001104659-26-050358 | | 2026-03-31 | 17:05 ET | [10-K](/filings/0001104659-26-037874.md) | Annual report, period 2025-12-31 | 0001104659-26-037874 | | 2026-03-31 | 16:15 ET | [8-K](/filings/0001104659-26-037749.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-26-037749 | | 2026-03-30 | 17:30 ET | [8-K](/filings/0001104659-26-036818.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-036818 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001104659-26-037874.md), filed Mar 31, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/7f75a4c5-eb4e-4cab-b4c6-9d1597aa152f) ## About the filer - CIK: 1429260 - Tickers: FBIO, FBIOP - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 29, 2026, 17:38 ET. No prices; not investment advice.